Imbruvica combo on course for CLL nod

25 May 2018

Imbruvica is already approved as a monotherapy for first-line chronic lymphocytic leukemia (CLL), but new data is strengthening the case for the drug to also be used in this setting along with Gazyva (obinutuzumab).

That is good news for AbbVie (NYSE: ABBV) and its growth plans for the Bruton's tyrosine kinase inhibitor – along with the US drugmaker’s development and commercialization partner Janssen, part of the Johnson & Johnson (NYSE: JNJ) group.

The Phase III iLLUMINATE trial met its primary endpoint of improvement in progression-free survival (PFS) when combining Imbruvica with Roche’s (ROG: SIX) Gazyva in previously untreated CLL or small lymphocytic lymphoma (SLL) patients, the most common adult leukemia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK